Search

everythinglearnresearchcommunity

for

Search:↓

Some leukemia treatments can cause skin reactions similar to keratosis pilaris.

Upadacitinib effectively treated severe hair loss in a child.

Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.

Gefitinib can cause hair and eyebrow darkening.

CI-1033 causes skin lesions in rats, similar to humans, due to EGF receptor inhibition.

Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.

Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.

A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.

Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.

Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.

Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.

Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.

A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.

Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.

Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.

Upadacitinib effectively treats pyoderma gangrenosum.

Ritlecitinib was generally well tolerated in children with alopecia areata.

Tofacitinib helped a person with total body hair loss grow hair again without bad side effects.

Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.

MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

Abrocitinib helped a 14-year-old girl with severe alopecia areata regrow her hair significantly.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

Upadacitinib may effectively treat resistant lichen planopilaris.

A patient developed nerve problems as a side effect of a hair loss treatment called tofacitinib.

Pexidartinib often causes liver issues and fatigue, especially in women.

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

Tofacitinib helped psoriasis but not alopecia universalis, needing more research.

Tofacitinib may effectively treat folliculitis decalvans.